GHK-Cu vs Palmitoyl Tripeptide-1

The same GHK sequence with two different delivery strategies.

The distinction that mattersSame GHK tripeptide. GHK-Cu carries a copper ion and works partly by delivering copper; palmitoyl tripeptide-1 carries a fatty tail for penetration and delivers no copper.

	GHK-Cu Cosmetic Ingredient	Palmitoyl Tripeptide-1 Cosmetic Ingredient
Evidence rating	3/5 Moderate Evidence rating 3 out of 5: Moderate	3/5 Moderate Evidence rating 3 out of 5: Moderate
Regulatory status	Established cosmetic ingredient with human topical data. Injectable use is unapproved and unstudied.	Widely used cosmetic ingredient, typically paired with palmitoyl tetrapeptide-7 in commercial formulations.
Category	Skin & Cosmetic	Skin & Cosmetic
Drug class	Naturally occurring copper-binding tripeptide	Lipidated tripeptide — the GHK sequence conjugated to palmitic acid
Route	Topical (well studied); injectable (not studied)	Topical
Half-life	Commonly quoted as 30–60 minutes — that figure is an estimate repeated by suppliers and search summaries, not a measurement, and the same sources elsewhere give 1–2 hours or 4. No human pharmacokinetic study of GHK-Cu has been published for any route, so there is no measured half-life to report. What is established: rat work shows the tripeptide is cleared from plasma and broken to the dipeptide His-Lys, and once the peptide bonds are cut the copper does not leave with it but transfers to albumin, so the copper outlasts the peptide by far. Endogenous plasma GHK falls with age, but that is a concentration, not a half-life.	Not applicable — topical
Sequence length	3 residues	3 residues
Molecular weight	401.9 Da	578.8 Da
Studied in	A handful of small controlled human studies: a randomised, evaluator-blinded, vehicle-controlled trial of a copper tripeptide gel in diabetic foot ulcers (whose larger 511-patient successor failed), a maker-funded 8-week split-face wrinkle trial in 40 women, a small trial after laser resurfacing that was negative on blinded measures, and an 18-person eyebrow study. The cosmetic facial and eye-cream results were reported as 2002 conference abstracts rather than papers, and no controlled trial supports GHK-Cu alone for scalp hair. The bulk of the literature is fibroblast and keratinocyte culture plus rodent wound, lung and liver models. No controlled human study of any injected route.	Controlled topical studies of the combination product measuring wrinkle depth and dermal density; fibroblast and ex-vivo skin work.
Who should avoid it	Wilson disease or copper metabolism disorders (systemic use) Known copper allergy Broken or actively infected skin without medical advice	Known ingredient allergy Broken or actively irritated skin
Legal status	Lawful as a cosmetic ingredient. Injectable preparations are unapproved.	Lawful cosmetic ingredient.

Benefits — GHK-Cu

Improved skin firmness and wrinkle depth
Small facial studies reported modest improvements in wrinkle depth, skin density and elasticity against comparison creams. The best, a randomised 8-week split-face trial, was maker-funded and could not separate GHK-Cu from its carrier; the older cream studies exist only as conference abstracts.
Wound healing acceleration
A randomised, blinded trial found faster closure of diabetic foot ulcers, but the maker's larger 511-patient trial failed. Animal wound studies consistently show faster closure and better-organised collagen.
Collagen and elastin stimulation
Robust fibroblast data showing upregulation of matrix synthesis.
Hair follicle effects
Cell and animal work shows effects on hair-follicle cells. No controlled trial of GHK-Cu alone has tested scalp hair loss; the human trial usually cited used a copper-free GHK compound.
Antioxidant and anti-inflammatory activity
Reduces oxidative damage markers in laboratory models.

Benefits — Palmitoyl Tripeptide-1

Wrinkle depth reduction in controlled studies
Combination products showed measurable improvement in wrinkle depth and skin smoothness versus vehicle over 8–12 weeks.
Collagen and matrix stimulation
Consistent fibroblast data for increased collagen I, III and IV, plus fibronectin and hyaluronic acid.
Better penetration than unmodified GHK
The palmitoyl chain solves the delivery problem that limits most topical peptides.
Complementary anti-inflammatory partner
The paired tetrapeptide-7 targets IL-6-driven matrix degradation, a different mechanism from collagen stimulation.
Very well tolerated
Suitable for sensitive skin and compatible with most other actives.

Risks & cons — GHK-Cu

Injectable use has no evidence base
The credible data is topical. Injecting copper peptides for systemic anti-aging has not been studied and introduces copper-load questions.
Copper accumulation concern
Chronic high-dose systemic copper exposure carries hepatic and neurologic risk; contraindicated in Wilson disease.
Skin irritation and contact dermatitis
Occurs in a minority of topical users, more often at higher concentrations.
Incompatibility with vitamin C and some acids
Direct co-application can destabilise the complex; separate application times are advised.
Wide variation in product concentration
Cosmetic products differ enormously in actual GHK-Cu content and formulation quality.

Risks & cons — Palmitoyl Tripeptide-1

Effect sizes are modest
Real but incremental. It will not approach the results of retinoids at effective concentrations, or procedural treatments.
Evidence largely from ingredient suppliers
Most supporting studies are manufacturer-sponsored, and independent replication is limited.
Combination products obscure attribution
Because it is nearly always sold with tetrapeptide-7, the individual contribution of each peptide is unclear.
Concentration rarely disclosed
Products vary widely and often contain far less than the studied concentration.
Requires continuous use
Benefits regress once application stops.

A comparison is not a recommendation. Neither column is being suggested for you. Which — if either — is appropriate depends on your diagnosis, history and medications, and that is a conversation for a qualified clinician.